Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2013

View Archived Issues

Eisai presents highlights of first quarter of fiscal 2013

Otsuka updates accomplishments of second quarter 2013

Novel biomarker is associated with response to anti-EGFR cancer treatment

Preclinical characterization of a GIP analogue for the treatment of diabetes

Celgene presents phase III results for nab-paclitaxel in metastatic melanoma

Grafix shows efficacy in stem cell study for diabetic foot ulcers

Reliable insulin delivery seen with Adagio inhalable insulin in phase I/II trial

A novel COX-2 inhibitor shows potential as adjuvant radiosensitizer in melanoma cell lines

Lilly's phase III trial of necitumumab in NSCLC meets primary endpoint of overall survival

Atlantic Pharmaceuticals completes pre-IND meeting with FDA for abuse-deterrent hydrocodone

Patrys discloses additional data from phase I/II trial of PAT-SM6 in MM

Trial of CPX-351 in high-risk leukemia and myelodysplastic syndrome initiated

Myelin Repair Foundation and Gencia Corporation to collaborate on multiple sclerosis therapeutics

AdvanDx launches Gram-Negative QuickFISH BC assay

GW Pharmaceuticals opens U.S. IND application for phase III Sativex program

Taisho Pharmaceutical presents new mGlu2 receptor antagonists

Sanford-Burnham and Pfizer to identify targets for treatment of diabetes

Japanese researchers patent novel agents for promoting osteogenesis

FDA approves liquid form of enalapril

Eli Lilly discloses new MGAT2 inhibitors for hypertriglyceridemia

Acasti Pharma reports data from phase II CaPre trial

Suda acquires NovaDel Pharma assets

Altor receives IND clearance to advance ALT-803 into clinical trials in melanoma

Mallinckrodt submits results from PK study requested by FDA in response to Pennsaid 2% NDA

ALN-AT3 receives orphan drug designation from the FDA

Boehringer Ingelheim enters agreement to study real-world use of oral anticoagulants

Dosing begins in phase I study of DX-2930

Cedars-Sinai begins phase I trial of Copaxone as immunization for Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...